- CheckMate 227 Reveals Tumour Mutational Burden as an Important and Independent Biomarker in Advanced NSCLC
- FDA Approves Nivolumab/Ipilimumab Combination for Intermediate or Poor-Risk Advanced RCC
- ESMO Immuno-Oncology Congress 2018: Abstracts
- FDA Finalises Guidances to Accelerate the Development of Reliable, Beneficial NGS-Based Tests
- EMA to Review Risk of Dosing Errors with Methotrexate
- ELCC 2018 News: New Data Support First-Line Osimertinib in Patients with NSCLC and Sensitising EGFR Mutation
Providing practical opinion to support best practice for busy healthcare professionals